Rain Therapeutics Inc. RAIN
We take great care to ensure that the data presented and summarized in this overview for Rain Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RAIN
Top Purchases
Top Sells
About RAIN
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Insider Transactions at RAIN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2024
|
Tang Kevin C |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,850,513
-100.0%
|
-
|
|
Jan 26
2024
|
Peter Radovich Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,796
-100.0%
|
-
|
|
Jan 26
2024
|
Aaron I. Davis Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
79,726
-100.0%
|
-
|
|
Jan 26
2024
|
Avanish Vellanki Chairman and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,550,910
-100.0%
|
-
|
|
Jan 26
2024
|
Robert Doebele Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
476,827
-100.0%
|
-
|
|
Jan 26
2024
|
Franklin M Berger Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,005,207
-100.0%
|
-
|
|
Jan 25
2024
|
Bvf Partners L P Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,288,617
-100.0%
|
-
|
|
Jan 25
2024
|
Bvf Partners L P Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,288,186
-100.0%
|
-
|
|
Dec 18
2023
|
Tang Kevin C |
SELL
Open market or private sale
|
Indirect |
40,132
-1.03%
|
$40,132
$1.21 P/Share
|
|
Dec 15
2023
|
Tang Kevin C |
SELL
Open market or private sale
|
Indirect |
109,435
-2.74%
|
$109,435
$1.2 P/Share
|
|
Dec 14
2023
|
Tang Kevin C |
SELL
Open market or private sale
|
Indirect |
24,406
-0.61%
|
$24,406
$1.21 P/Share
|
|
Oct 13
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
131,631
+1.62%
|
$0
$0.99 P/Share
|
|
Oct 12
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
77,702
+0.99%
|
$0
$0.98 P/Share
|
|
Oct 11
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
74,812
+1.92%
|
$0
$0.97 P/Share
|
|
Jun 01
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
333,325
+4.31%
|
$333,325
$1.11 P/Share
|
|
May 31
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
166,180
+2.34%
|
$166,180
$1.09 P/Share
|
|
May 30
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
588,768
+3.51%
|
$588,768
$1.05 P/Share
|
|
May 22
2023
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
995,000
-46.34%
|
$995,000
$1.25 P/Share
|
|
Nov 22
2022
|
Franklin M Berger Director |
BUY
Open market or private purchase
|
Direct |
77,000
+7.12%
|
$616,000
$8.27 P/Share
|
|
Nov 21
2022
|
Franklin M Berger Director |
BUY
Open market or private purchase
|
Direct |
45,000
+4.62%
|
$315,000
$7.8 P/Share
|
Last 12 Months Summary
| Disposition due to a tender of shares in a change of control transaction | 16.5M shares |
|---|---|
| Open market or private sale | 174K shares |